EN/中文
Menu

Business

Service Characteristics

CDMO business is committed to providing global innovative drug partners with one-stop services for small molecule APIs and intermediates from preclinical to commercial stages

  • Lab & pilot scale for intermediates and APIs of innovative drug research;
  • CMC development optimization and quality research of innovative drug intermediates and APIs;
  • Commercial production of innovative drug intermediates and APIs, divided into non-GMP and cGMP based on customer needs;
  1. Leading technical level

    Deeply involved in the CDMO field for more than 10 years, we continue to drive technological innovation and are leading in flow chemistry, bio-catalysis and other fields. We have excellent R&D team specializing in various chemical synthesis reactions

  2. Adequate production capacity

    Our own CDMO plant and cooperated factories with 50L to 5000L reactors which can meet the different needs of customers from lab scale to commercial production.

  3. Strong delivery capacity

    The team members have rich project experience and excellent industry evaluation, they can Deliver timely according to customer's project requirements and ensure the project is carried out on time

  4. Perfect quality system

    We have a perfect quality system to meet the production requirements of cGMP and have successfully passed many audits by the official and customers over the past three years

Kg laboratory

The R&D center of Nanjing Vcare has 5 kilo-labs (including new technology lab and hydrogenation room), with total of 50 walk-in fume hoods, 30 reactors from 20L to 100L, covering -100 degrees Celsius to 180 degrees Celsius, providing customers with kg-scale preclinical and R&D samples supply.

CDMO Plant

Hubei Tianshu Pharmaceutical Co., LTD.

As a production base of Nanjing Vcare, Tianshu Pharma plays an important role in the layout of the whole industry chain of ' Chemistry + Pharmacy + Medicine ';Tianshu Pharmaceutical is located in Xiangyang (Yicheng) Fine Chemical Industrial Park, a Hubei Provincial Chemical Park, covering an area of 130 mu. Phase Ⅰof the project has been built and put into production, with a built-up area of 20,000 ㎡and a production capacity of about 255 m³, and is now a high-tech enterprise.

  • 0 mu.

    Covering an area

  • 0

    Floor area of (Phase Ⅰ)

  • 0

    The capacity of (Phase Ⅰ)

The 1st phase of Tianshu Pharma includes an API workshop and an intermediate workshop. The API workshop is around 2,000 square meters, including a non-cytotoxic oncology production line and a general production line, with a total of 34 reactors and the capacity is around 55 m³. The intermediate workshop is around 3,000 square meters, including 9 production lines (one hydrogenation line), with more than 100 reactors ( high and low temperature and hydrogenation) , and the capacity is around 200 m³.The plant is designed and built in strict accordance with the rules of FDA and cGMP to meet the requirements of regulated market.

Tianshu Pharmaceutical plans four production workshops in the Phase Ⅱ, all of which are designed and constructed according to high standards and are planned to be put into use in 2025, when the production capacity will be further improved to meet the output needs of more customers.

Copyright © Nanjing Vcare PharmaTech Co.,Ltd. All rights reserved 苏ICP备2023020715号-1
Links: Vcarepharmatech Support Privacy Policy